|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Antibacterials
Datamonitor, Feb 2011, Pages: 149
Introduction
The antibacterial pipeline is robust with regards to new drugs for the treatment of Gram-positive pathogens, particularly methicillin-resistant Staphylococcus aureus (MRSA). However, there is a lack of late-stage candidates for Gram-negative pathogens. Datamonitor believes that the launch of nine new drugs during the forecasted period (2010–19) will inject $1.98bn into the antibacterial market.
Features and benefits
- Overview of the antibacterial drugs pipeline across the US, Japan, France, Italy, Germany, Spain and the UK.
- Detailed ten-year sales forecasts for key late-stage pipeline antibacterial drugs in each of the seven major markets.
- Discussion of unmet needs driving the sales prospects for new antibacterials.
- Review of R&D trends and clinical trial design in the antibacterials sector.
Highlights
- Among the late-stage antibacterial pipeline drugs, Trius Therapeutics/Dong-A Pharmaceutical‘s torezolid, Forest Laboratories/Takeda/Abbott’s ceftaroline fosamil and Paratek/Novartis’ PTK 0796 have the best outlook.
- Whereas the Gram-positive segment is relatively well covered, the most important unmet need in antibacterials lies in the development of efficacious drugs against resistant gram-negative pathogens such as Pseudomonas, Acinetobacter or Klebsiella.
- Antibacterial drug developers are currently primarily targeting the high-price hospital market with a key focus on multidrug-resistant pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA).
Your key questions answered
- Assess and quantify the market opportunity for late-stage pipeline antibacterials.
- Understand the changing market dynamics of antibacterial drugs, unmet needs and success factors for pipeline candidates.
- Assess the impact of key issues affecting the antibacterials pipeline; competition, generic erosion and growing levels of resistance.
|
|
|
|
